Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3810210
Max Phase: Preclinical
Molecular Formula: C30H22ClN3O4
Molecular Weight: 523.98
Molecule Type: Small molecule
Associated Items:
ID: ALA3810210
Max Phase: Preclinical
Molecular Formula: C30H22ClN3O4
Molecular Weight: 523.98
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: COc1cccc2c(/C=C/C(=O)Nc3cccc(/C=C/c4ccc5ccc(Cl)cc5n4)c3)c(C(=O)O)[nH]c12
Standard InChI: InChI=1S/C30H22ClN3O4/c1-38-26-7-3-6-23-24(29(30(36)37)34-28(23)26)14-15-27(35)33-22-5-2-4-18(16-22)8-12-21-13-10-19-9-11-20(31)17-25(19)32-21/h2-17,34H,1H3,(H,33,35)(H,36,37)/b12-8+,15-14+
Standard InChI Key: BCDSYHCOCSCCQZ-CCQVQAEASA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 523.98 | Molecular Weight (Monoisotopic): 523.1299 | AlogP: 6.90 | #Rotatable Bonds: 7 |
Polar Surface Area: 104.31 | Molecular Species: ACID | HBA: 4 | HBD: 3 |
#RO5 Violations: 2 | HBA (Lipinski): 7 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 3.74 | CX Basic pKa: 3.02 | CX LogP: 5.96 | CX LogD: 3.09 |
Aromatic Rings: 5 | Heavy Atoms: 38 | QED Weighted: 0.20 | Np Likeness Score: -0.70 |
1. Chen H, Yang H, Wang Z, Xie X, Nan F.. (2016) Discovery of 3-Substituted 1H-Indole-2-carboxylic Acid Derivatives as a Novel Class of CysLT1 Selective Antagonists., 7 (3): [PMID:26985325] [10.1021/acsmedchemlett.5b00482] |
Source(1):